Protective Effects of Dexmedetomidine Against Ischemic Heart Disease and Diabetic Cardiomyopathy by Targeting Ferroptosis

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Cardiovascular diseases (CVDs) are a major global health burden, with ischemic heart disease and diabetic cardiomyopathy causing significant myocardial injury.
• Key mechanisms of myocardial injury include calcium overload, mitochondrial damage, reactive oxygen species (ROS) accumulation, and abnormal programmed cell death (PCD) pathways like ferroptosis.
• Dexmedetomidine (DEX), an α2-adrenergic agonist, is used for sedation and analgesia and is increasingly recognized for its cardioprotective potential.

Purpose of the Study:

• To review the role of ferroptosis in myocardial injury in ischemic heart disease and diabetic cardiomyopathy.
• To elucidate the regulatory mechanisms of Dexmedetomidine (DEX) in ferroptosis pathways.
• To highlight DEX's potential therapeutic benefits for CVDs.

Main Methods:

• Literature review and synthesis of existing research on ferroptosis in cardiovascular diseases.
• Analysis of studies investigating Dexmedetomidine's effects on oxidative stress, mitochondrial function, and PCD pathways.
• Focus on the mechanistic link between DEX and ferroptosis regulation.

Main Results:

• Ferroptosis is a critical pathway contributing to myocardial damage in ischemic heart disease and diabetic cardiomyopathy.
• Dexmedetomidine (DEX) demonstrates significant potential in reducing oxidative stress, inflammation, and improving mitochondrial function.
• Emerging evidence suggests DEX actively modulates ferroptosis, offering a novel therapeutic avenue.

Conclusions:

• Ferroptosis plays a crucial role in the pathogenesis of ischemic heart disease and diabetic cardiomyopathy.
• Dexmedetomidine (DEX) exhibits promising cardioprotective effects, partly through the regulation of ferroptosis.
• Further research into DEX's ferroptosis-modulating mechanisms could lead to new treatments for CVDs.